We present a proof of concept for a CAR T cell immunotherapy approach to targeting chronic myeloid leukemia (CML) or acute myeloid leukemia (AML) leukemic stem cells that express interleukin-1 receptor accessory protein (IL-1RAP) [22]. This evidence concerns the gene IL1RAP and acute myeloid leukemia.